CN106902083A - A kind of colistin sulfate soluble powder and compound method used in outlet fowl - Google Patents
A kind of colistin sulfate soluble powder and compound method used in outlet fowl Download PDFInfo
- Publication number
- CN106902083A CN106902083A CN201710124042.XA CN201710124042A CN106902083A CN 106902083 A CN106902083 A CN 106902083A CN 201710124042 A CN201710124042 A CN 201710124042A CN 106902083 A CN106902083 A CN 106902083A
- Authority
- CN
- China
- Prior art keywords
- colistin sulfate
- soluble powder
- fowl
- colistin
- outlet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010078777 Colistin Proteins 0.000 title claims abstract description 38
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 title claims abstract description 36
- 229960001127 colistin sulfate Drugs 0.000 title claims abstract description 34
- 239000000843 powder Substances 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 26
- 102000004190 Enzymes Human genes 0.000 claims abstract description 14
- 108090000790 Enzymes Proteins 0.000 claims abstract description 14
- 229960002152 chlorhexidine acetate Drugs 0.000 claims abstract description 9
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims abstract description 9
- -1 colistin sulfates Chemical class 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 229960003346 colistin Drugs 0.000 claims description 4
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 4
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 208000017667 Chronic Disease Diseases 0.000 claims description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 4
- 238000001228 spectrum Methods 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 241000272525 Anas platyrhynchos Species 0.000 abstract description 2
- 241000588724 Escherichia coli Species 0.000 abstract description 2
- 208000007893 Salpingitis Diseases 0.000 abstract description 2
- 230000000843 anti-fungal effect Effects 0.000 abstract description 2
- 229940121375 antifungal agent Drugs 0.000 abstract description 2
- 206010034674 peritonitis Diseases 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 235000013330 chicken meat Nutrition 0.000 description 9
- 241000271566 Aves Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- ICVKYYINQHWDLM-KBEWXLTPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4 Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 ICVKYYINQHWDLM-KBEWXLTPSA-N 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- 229960003260 chlorhexidine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 229960001717 tylosin tartrate Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000027312 Bursal disease Diseases 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000009837 laryngotracheitis Diseases 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of colistin sulfate soluble powder and compound method used in outlet fowl, colistin sulfate soluble powder includes colistin sulfate 10%, medicine synergist, chlorhexidine acetate, gastridine and organized enzyme, the colistin sulfate soluble powder used in outlet fowl is mixed by colistin sulfate 10%, medicine synergist, chlorhexidine acetate, gastridine and organized enzyme, and this is used in the colistin sulfate soluble powder of outlet fowl to Escherichia coli（G‑）And pneumococcus（G+）Core bag liver caused by caused air bag inflammation and colibacillosis, duck oromeningitis, salpingitis of layer chicken, peritonitis has therapeutic action, and the present invention treats both principal and secondary aspect of disease, and culture is unique, and has a broad antifungal spectrum, present invention optimizes design, meets the requirement of design.
Description
Technical field
The present invention relates to birds antibacterium technical field, and in particular to a kind of Tylosin Tartrate for birds is solvable
Property powder compound method.
Background technology
With the development and the raising of living standards of the people of society, increasing people begins to focus on food-safety problem；
In China, poultry industry scale expands day by day；But due to the limitation of rearing conditions, poultry disease is propagated more universal；Poultry
Most commonly seen in breeding process is viral disease, mainly including newcastle disease（NDV）, viral respiratory is sick and chronic exhales
Inhale road disease, infectious bronchitis of chicken, Bursal Disease, bird flu, infectious laryngotracheitis of chicken, chicken viral joint
Scorching, chicken egg-decreasing syndrome, the bacteriosis of birds mainly includes Escherichia coli（G-）And pneumococcus（G+）Caused air bag
Core bag liver, duck oromeningitis, salpingitis of layer chicken, peritonitis caused by scorching and colibacillosis.
At present, in the prior art preventing and treating chicken viral diseases and chicken bacteriosis mainly using Western medicine, immunoprophylaxis and
Herbal control；There are problems that：
1. spreading unchecked for Western medicine brings great potential safety hazard using to chicken meat product, and medicament residue has become influence chicken peace
Full principal element；
2. immunoprophylaxis are preferable in early stage results, however it is necessary that being repeatedly inoculated with, troublesome poeration is relatively costly, easily causes chick
Stress reaction, and vaccine is more harsh for the requirement of storage conditions, it is necessary to be refrigerated under the conditions of 2~8 DEG C, room temperature condition is next
The section time then loses effect；
3., though Chinese herbal feed additive is one of current research direction, the species of Chinese herbal medicine is more, identical medicinal material pair
The difference between the effects of different diseases of bird and livestock are larger, and immune raising of the Chinese herbal medicine to disease is extremely limited, therefore its application also has
Certain limitation；
4. injection Yolk antibody is also a kind of relatively conventional method, but the immune effect of single injection Yolk antibody is sometimes
Can not meet and be actually needed.
The content of the invention
To solve the above problems, the present invention proposes a kind of tylosin tartrate soluble powder preparation side for birds
Method.
To realize the object of the invention, the technical scheme of use is：A kind of colistin sulfate soluble powder used in outlet fowl
And compound method, colistin sulfate soluble powder include colistin sulfate 10%, medicine synergist, chlorhexidine acetate, dipropyl paddy acyl
Amine and organized enzyme, the colistin sulfate soluble powder used in outlet fowl is by colistin sulfate 10%, medicine synergist, acetic acid
Chlorhexidine, gastridine and organized enzyme are mixed.
Preferably, the usage and dosage of described colistin sulfate soluble powder is：100g colistin sulfates soluble powder with
200Kg water mixes, and dose needed for whole day is concentrated and is finished within 4-6 hours, is used in conjunction 3 days, without dosage, wherein, chronic disease is extended and is treated
Journey.
Preferably, the packing specification of described colistin sulfate soluble powder is：100g/ bags × 100 bags/case.
Compared with prior art, the beneficial effects of the invention are as follows：A kind of sulfuric acid used in outlet fowl involved in the present invention
Colistin soluble powder and compound method, colistin sulfate soluble powder include colistin sulfate 10%, medicine synergist, acetic acid
Chlorhexidine, gastridine and organized enzyme, it is described used in outlet fowl colistin sulfate soluble powder by colistin sulfate 10%,
Medicine synergist, chlorhexidine acetate, gastridine and organized enzyme are mixed, with advantages below：
1. inventive formulation is unique, has a broad antifungal spectrum：Described colistin sulfate forms drug concentration higher in enteron aisle, to intestines
Mucous membrane antiinflammation is powerful, and medicine synergist is not influenceed by food, hence it is evident that expands the antimicrobial spectrum of this product, has strong to bacterium
Killing action, is one group of perfect formula combination, and the two can Synergistic, improve the therapeutic action of this product；
2. bioavilability of the present invention is high：Described organized enzyme can promote the absorption of medicine, improve medicine and enter blood rate 30% or so,
The blood concentration of medicine is high, more effectively kills pathogenic bacteria；
3. the present invention is quick reduces dead：Described organized enzyme decomposable asymmetric choice net air bag, the fibrin of liver and heart secretion and
Collagen, the quick death rate for reducing sick fowl；
4. chlorhexidine acetate of the present invention is new erosion prevention and muscle growing medicine, stimulates focal part blood vessel dilatation, leucocyte
Increase, so as to eliminate focus rapidly, promote the reparation of impaired serous coat；
5. gastridine of the present invention orally absorbs quickly, protects intestinal mucosa, promotes the healing of enteron aisle ulcer surface, while
The spasm of intestinal smooth, the function of recuperating gastrointestinal tract can also be released；
The present invention in summary medicinal property, is medicine that fowl bacterial disease is treated both principal and secondary aspect of disease.
Brief description of the drawings
Fig. 1 is the preparation raw material table of the colistin sulfate soluble powder that the present invention is used in outlet fowl.
Specific embodiment
Below in conjunction with the accompanying drawing in the embodiment of the present invention, the technical scheme in the embodiment of the present invention is carried out clear, complete
Site preparation is described, it is clear that described embodiment is only a part of embodiment of the invention, rather than whole embodiments.It is based on
Embodiment in the present invention, it is every other that those of ordinary skill in the art are obtained under the premise of creative work is not made
Embodiment, belongs to the scope of protection of the invention.
Embodiment 1
Refer to shown in Fig. 1, the technical solution adopted by the present invention is：It is a kind of used in outlet fowl colistin sulfate soluble powder and
Compound method, colistin sulfate soluble powder includes colistin sulfate 10%, medicine synergist, chlorhexidine acetate, dipropyl paddy acyl
Amine and organized enzyme, the colistin sulfate soluble powder used in outlet fowl is by colistin sulfate 10%, medicine synergist, acetic acid
Chlorhexidine, gastridine and organized enzyme are mixed.
Operation principle：When using, described colistin sulfate forms drug concentration higher in enteron aisle, and intestinal mucosa is disappeared
Scorching powerful, medicine synergist is not influenceed by food, hence it is evident that expand the antimicrobial spectrum of this product, has strong killing to make to bacterium
With, be one group of perfect formula combination, and the two can Synergistic, improve the therapeutic action of this product；Described organized enzyme
The absorption of medicine can be promoted, medicine is improved and entered blood rate 30% or so, the blood concentration of medicine is high, more effectively kills pathogenic bacteria；Institute
The fibrin and collagen of organized enzyme decomposable asymmetric choice net air bag, liver and the heart secretion stated, the quick death for reducing sick fowl
Rate；Described chlorhexidine acetate is new erosion prevention and muscle growing medicine, stimulation focal part blood vessel dilatation, leukocytosis, so that
It is rapid to eliminate focus, promote the reparation of impaired serous coat；Described gastridine orally absorbs quickly, protects intestinal mucosa, promotes
The healing of enteron aisle ulcer surface, while the spasm of intestinal smooth can also be released, the function of recuperating gastrointestinal tract.
Wherein, the usage and dosage of described tylosin tartrate soluble powder is：100g Tylosin Tartrates are solvable
Property powder mix with 200Kg water, by needed for whole day dose concentrate be finished within 4-6 hours, one time one day, be used in conjunction 3 days, wherein, severe adds
Amount is used.
Wherein, the packing specification of described colistin sulfate soluble powder is：100g/ bags × 100 bags/case.
Although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
Understanding can carry out various changes, modification, replacement to these embodiments without departing from the principles and spirit of the present invention
And modification, the scope of the present invention be defined by the appended.
Claims (3)
1. a kind of used in the colistin sulfate soluble powder and compound method that export fowl, colistin sulfate soluble powder includes sulfuric acid
Colistin 10%, medicine synergist, chlorhexidine acetate, gastridine and organized enzyme, it is characterised in that：It is described used in outlet fowl
Colistin sulfate soluble powder by colistin sulfate 10%, medicine synergist, chlorhexidine acetate, gastridine and organized enzyme
It is mixed.
2. colistin sulfate soluble powder according to claim 1, it is characterised in that：Described colistin sulfate is soluble
The usage and dosage of powder is：100g colistin sulfates soluble powder mixes with 200Kg water, and dose needed for whole day is concentrated 4-6 hours
It is finished, is used in conjunction 3 days, without dosage, wherein, chronic disease is extended the period for the treatment of.
3. colistin sulfate soluble powder according to claim 1, it is characterised in that：Described colistin sulfate is soluble
The packing specification of powder is：100g/ bags × 100 bags/case.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710124042.XA CN106902083A (en) | 2017-03-03 | 2017-03-03 | A kind of colistin sulfate soluble powder and compound method used in outlet fowl |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710124042.XA CN106902083A (en) | 2017-03-03 | 2017-03-03 | A kind of colistin sulfate soluble powder and compound method used in outlet fowl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106902083A true CN106902083A (en) | 2017-06-30 |
Family
ID=59186266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710124042.XA Pending CN106902083A (en) | 2017-03-03 | 2017-03-03 | A kind of colistin sulfate soluble powder and compound method used in outlet fowl |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106902083A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101648001A (en) * | 2009-09-22 | 2010-02-17 | 天津市海纳德动物药业有限公司 | Veterinary compound apramycin sulfate soluble powder and application thereof |
| CN101653596A (en) * | 2008-08-22 | 2010-02-24 | 天津生机集团股份有限公司 | Soluble powder for treating canine colibacillosis and preparation method thereof |
| CN101653417A (en) * | 2008-08-22 | 2010-02-24 | 天津生机集团股份有限公司 | Compound colistin sulfate soluble powder for treating lamb dysentery and preparation method thereof |
| CN101670094A (en) * | 2009-08-07 | 2010-03-17 | 天津生机集团股份有限公司 | Compound gentamycin sulfate soluble powder and preparation method thereof |
| CN105030744A (en) * | 2015-07-09 | 2015-11-11 | 广州英赛特生物技术有限公司 | Application of substituted benzene guanidine derivative serving as polymyxins antibiotic potentiator |
-
2017
- 2017-03-03 CN CN201710124042.XA patent/CN106902083A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101653596A (en) * | 2008-08-22 | 2010-02-24 | 天津生机集团股份有限公司 | Soluble powder for treating canine colibacillosis and preparation method thereof |
| CN101653417A (en) * | 2008-08-22 | 2010-02-24 | 天津生机集团股份有限公司 | Compound colistin sulfate soluble powder for treating lamb dysentery and preparation method thereof |
| CN101670094A (en) * | 2009-08-07 | 2010-03-17 | 天津生机集团股份有限公司 | Compound gentamycin sulfate soluble powder and preparation method thereof |
| CN101648001A (en) * | 2009-09-22 | 2010-02-17 | 天津市海纳德动物药业有限公司 | Veterinary compound apramycin sulfate soluble powder and application thereof |
| CN105030744A (en) * | 2015-07-09 | 2015-11-11 | 广州英赛特生物技术有限公司 | Application of substituted benzene guanidine derivative serving as polymyxins antibiotic potentiator |
Non-Patent Citations (3)
| Title |
|---|
| 张仁俊等主编: "《实用眼科药物学》", 30 September 2015, 人民军医出版社 * |
| 徐叔云主编: "《现代实用临床药理学》", 31 May 1997, 华夏出版社 * |
| 耿宝琴等主编: "《处方手册》", 30 September 2000, 浙江科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10265361B2 (en) | Feed additive for swine and feed composition containing the same | |
| Awaad et al. | Effect of a specific combination of carvacrol, cinnamaldehyde, and on the growth performance, carcass quality and gut integrity of broiler chickens. | |
| CN111705042A (en) | Pasteurella phage vB _ PmuP _ PS02, phage composition and application thereof | |
| CN110201142A (en) | A kind of compound preparation and preparation method thereof for preventing and treating hen salpingitis | |
| JPH03198747A (en) | Disease-preventive feed and feed additive for cattle and pig | |
| JP2018501294A (en) | Application of taurine in the prevention and / or treatment of diseases caused by coronavirus and / or rotavirus viruses | |
| CN106902083A (en) | A kind of colistin sulfate soluble powder and compound method used in outlet fowl | |
| Poorghasemi et al. | Effect of dietary inclusion of lemon balm (melissa officinalis l.) extract on performance, gut microflora, blood parameters, immunity and carcass traits of broilers | |
| CN109691596A (en) | A kind of broiler chicken intestinal mucosa renovation agent | |
| CN101269164B (en) | Method of preparing virus bacterium blood serum Chinese aloe vaccine powder preparation and oral liquid for livestock, poultry biology and aquatic animal | |
| Ellakany et al. | Studies on the effects of enrofloxacin overdose on different health parameters in broiler chickens | |
| CN104840591B (en) | A kind of Chinese medicine composition for having effects that to prevent ewcastle disease | |
| CN106902082A (en) | A kind of tylosin tartrate soluble powder compound method for birds | |
| CN103705568A (en) | Compound levofloxacin hydrochloride soluble powder for treating respiratory diseases of poultry | |
| CN101279028A (en) | Oral liquid vaccine for preventing and controlling avian influenza of domestic animals and domestic birds and method of preparing the same | |
| CN106605787A (en) | Feed additive for breeding laying ducks | |
| CN101326968B (en) | Animal feed additives using Zedoary turmeric oil as principal ingredient and preparation thereof | |
| CN105878286A (en) | Veterinary drug for preventing and treating plague in poultry and preparation method of veterinary drug | |
| CN105287852B (en) | One breeder clearing heat and detoxicating composition and preparation method thereof and feed | |
| CN109985022B (en) | Povidone iodine preparation and its preparing method and use | |
| RU2792118C1 (en) | Method for treatment of respiratory syncytial infection of cattle | |
| CN108310140A (en) | It is a kind of to be used to prevent pharmaceutical composition of infectious laryngotracheitis of chicken and its preparation method and application | |
| RU2791454C1 (en) | Method for treatment of viral diarrhea of young cattle | |
| CN106728619A (en) | A kind of composition for preventing and treating fish streptococcosis | |
| CN106421079A (en) | Traditional Chinese medicine composition for preventing chicken paratyphoid fever and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170630 |